Home › Funds › Catalio Capital Management, LP › ASND
Catalio Capital Management, LP position in ASND
ASCENDIS PHARMA A/S · Health Care
Catalio Capital Management, LP reported holding 101,445 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$23.1M, representing 4.31% of its reported portfolio and ranking #6 among its reported holdings. Catalio Capital Management, LP has disclosed ASND holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's ASND position evolved
Catalio Capital Management, LP first disclosed a stake in ASND in Q4 2024 at 215,587 shares (US$29.7M). The position peaked in Q2 2025 at 179,926 shares, worth US$31.1M. Across 8 filings, Catalio Capital Management, LP increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 101,445 shares valued at US$23.1M — an increase of 69,686 shares quarter over quarter.. Notable position changes include a 75% trim in Q2 2026 (shares fell 15% over the following quarter), a 219% increase in Q3 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 215.59K | $29.68M | New |
| Q1 2025 | 195.52K | $30.47M | Reduce |
| Q2 2025 | 179.93K | $31.06M | Reduce |
| Q3 2025 | 144.95K | $28.82M | Reduce |
| Q4 2025 | 119.27K | $25.43M | Reduce |
| Q1 2026 | 129.11K | $29.53M | Add |
| Q2 2026 | 31.76K | $8.47M | Reduce |
| Q3 2026 | 101.44K | $23.11M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 36 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.34B), T. Rowe Price Investment Management, Inc. (US$1.87B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.17B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.34B · Q3 2026
- T. Rowe Price Investment Management, Inc. 8.19M sh · $1.87B · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 5.13M sh · $1.17B · Q3 2026
- Avoro Capital Advisors LLC 5.05M sh · $1.15B · Q3 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.08M sh · $474.58M · Q3 2026
- PERCEPTIVE ADVISORS LLC 971.52K sh · $221.34M · Q3 2026
- Vestal Point Capital, LP 740.00K sh · $168.59M · Q3 2026
- ORBIMED ADVISORS LLC 345.20K sh · $78.65M · Q3 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held ASND?
Catalio Capital Management, LP has disclosed ASND holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Catalio Capital Management, LP's current position in ASND?
As of Q3 2026, Catalio Capital Management, LP holds 101.44K shares of ASND (ASCENDIS PHARMA A/S), valued at $23.11M, representing 4.31% of its reported portfolio and ranking #6.
Has Catalio Capital Management, LP been buying or selling ASND?
In the latest 13F filing (Q3 2026), Catalio Capital Management, LP increased its position in ASND. The position peaked in Q2 2025 at 179.93K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., WESTFIELD CAPITAL MANAGEMENT CO LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.